Humanized cobra venom factor: Structure, activity, and therapeutic efficacy in preclinical disease models

Molecular Immunology

Volumn 61, Issue 2, 2014, Pages 191-203

  Vogel, Carl Wilhelm ^a,b   Finnegan, Paul W ^c   Fritzinger, David C ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c Del Mar Bio Consulting   (United States)

Author keywords

Cobra venom factor (CVF); Complement depletion; Complement therapeutics; Humanized cobra venom factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; COBROTOXIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3C; RITUXIMAB;

ADAPTIVE IMMUNITY; ANTIPHOSPHOLIPID SYNDROME; ASTHMA; B CELL LYMPHOMA; BIOLOGICAL ACTIVITY; BULLOUS PEMPHIGOID; CHEMICAL STRUCTURE; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; CRYSTAL STRUCTURE; HEMOLYTIC UREMIC SYNDROME; HEMOPHILIA A; HUMAN; HYPERACUTE GRAFT REJECTION; IMMUNOGENICITY; INNATE IMMUNITY; INTESTINE ISCHEMIA; LUPUS ERYTHEMATOSUS; MYASTHENIA GRAVIS; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHYSICAL CHEMISTRY; PRIMATE; PRIORITY JOURNAL; PULMONARY ARTERY; REPERFUSION INJURY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; VENTILATOR INDUCED LUNG INJURY; XENOTRANSPLANTATION;

PRIMATES;

COBRA VENOM FACTOR (CVF); COMPLEMENT DEPLETION; COMPLEMENT THERAPEUTICS; HUMANIZED COBRA VENOM FACTOR;

ANIMALS; COBRA VENOMS; COMPLEMENT INACTIVATING AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; RECOMBINANT FUSION PROTEINS;

EID: 84907598669     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2014.06.035     Document Type: Review

References (141)

1. Alper C.A., Balavitch D. Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement). Science 1976, 191:1275-1276.
2. Alsenz J., Avila D., Huemer H.P., Esparza I., Becherer J.D., Kinoshita T., Wang Y., Oppermann S., Lambris J.D. Phylogeny of the third component of complement, C3: analysis of the conservation of human CR1, CR2, H, and B binding sites, concanavalin A binding sites, and thiolester bond in the C3 from different species. Dev. Comp. Immunol. 1992, 16:63-76.
3. Andrä J., Halter R., Kock M.A., Niemann H., Voge C.W., Paul D. Generation and characterization of transgenic mice expressing cobra venom factor. Mol. Immunol. 2002, 39:357-365.
4. Arroyave C.M., Stevenson D.D., Vaughan J.H., Tan E.M. Plasma complement changes during bronchospasm provoked in asthmatic patients. Clin. Allergy 1977, 7:173-182.
5. Arumugam T.V., Shiels I.A., Woodruff T.M., Granger D.N., Taylor S.M. The role of the complement system in ischemia-reperfusion injury. Shock 2004, 21:401-409.
6. Bammert H., Kunze B., Li Y., Fritzinger D.C., Bredehorst R., Vogel C.-W. Structure of the cobra venom factor (CVF) gene and comparison with the human C3 gene. Int. Immunopharmacol. 2002, 2:1275-1276.
7. Banda N.K., Levitt B., Glogowska M.J., Thurman J.M., Takahashi K., Stahl G.L., Tomlinson S., Arend W.P., Holers V.M. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J. Immunol. 2009, 183:5928-5937.
8. Bi L., Lawler A.M., Antonarakis S.E., High K.A., Gearhart J.D., Kazazian H.H. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat. Genet. 1995, 10:119-121.
9. Botto M., Kirschfink M., Macor P., Pickering M.C., Würzner R., Tedesco F. Complement in human diseases: lessons from complement deficiencies. Mol. Immunol. 2009, 46:2774-2783.
10. Botto M., Walport M.J. Hereditary deficiency of C3 in animals and humans. Int. Rev. Immunol. 1993, 10:37-50.
11. Brand D.D., Myers L.K., Terato K., Whittington K.B., Stuart J.M., Kang A.H., Rosloniec E.F. Characterization of the T cell determinants in the induction of autoimmune arthritis by bovine alpha 1(II)-CB11 in H-2q mice. J. Immunol. 1994, 152:3088-3097.
12. Busche M.N., Walsh M.C., McMullen M.E., Guikema B.J., Stahl G.L. Mannose-binding lectin plays a critical role in myocardial ischaemia and reperfusion injury in a mouse model of diabetes. Diabetologia 2008, 51:1544-1551.
13. Buyon J.P., Tamerius J., Ordorica S., Young B., Abramson S.B. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum. 1992, 35:55-61.
14. Christadoss P., Tüzün E., Li J., Saini S.S., Yang H. Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis. Ann. N. Y. Acad. Sci. 2008, 1132:210-219.
15. Circolo A., Garnier G., Fukuda W., Wang X., Hidvegi T., Szalai A.J., Briles D.E., Volanakis J.E., Wetsel R.A., Colten H.R. Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology 1999, 42:135-149.
16. Cochrane C.G., Müller-Eberhard H.J., Aikin B.S. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J. Immunol. 1970, 105:55-69.
17. Conti-Fine B.M., Milani M., Kaminski H.J. Myasthenia gravis: past, present, and future. J. Clin. Invest. 2006, 116:2843-2854.
18. Dall'Ozzo S., Tartas S., Paintaud G., Cartron G., Colombat P., Bardos P., Watier H., Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004, 64:4664-4669.
19. Dalmasso A.P. The complement system in xenotransplantation. Immunopharmacology 1992, 24:149-160.
20. de Bruijn M.H., Fey G.H. Human complement component C3: cDNA coding sequence and derived primary structure. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:708-712.
21. Delignat S., Repesse Y., Navarrete A.M., Meslier Y., Gupta N., Christophe O.D., Kaveri S.V., Lacroix-Desmazes S. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A. Haemophilia 2012, 18:248-254.
22. Di Gaetano N., Cittera E., Nota R., Vecchi A., Grieco V., Scanziani E., Botto M., Introna M., Golay J. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 2003, 171:1581-1587.
23. DiScipio R.G., Smith C.A., Müller-Eberhard H.J., Hugli T.E. The activation of human complement component C5 by a fluid phase C5 convertase. J. Biol. Chem. 1983, 258:10629-10636.
24. Edwards A.O., Ritter R., Abel K.J., Manning A., Panhuysen C., Farrer L.A. Complement factor H polymorphism and age-related macular degeneration. Science 2005, 308:421-424.
25. Eggertsen G., Lind P., Sjöquist J. Molecular characterization of the complement activating protein in the venom of the Indian cobra (Naja N. siamensis). Mol. Immunol. 1981, 18:125-133.
26. Eggertsen G., Lundwall A., Hellman U., Sjöquist J. Antigenic relationships between human and cobra complement factors C3 and cobra venom factor (CVF) from the Indian cobra (Naja naja). J. Immunol. 1983, 131:1920-1923.
27. Ehrenforth S., Kreuz W., Scharrer I., Linde R., Funk M., Gungor T., Krackhardt B., Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992, 339:594-598.
28. Ferreira V.P., Pangburn M.K. Factor H mediated cell surface protection from complement is critical for the survival of PNH erythrocytes. Blood 2007, 110:2190-2192.
29. Fritzinger D.C., Vogel C.-W., Damaj B.B., Finnegan P.W. An inhibitory role of complement in monoclonal antibody therapy of lymphoma. Mol. Immunol. 2010, 47:2268.
30. Fritzinger D.C., Bredehorst R., Vogel C.-W. Molecular cloning and derived primary structure of cobra venom factor. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:12775-12779.
31. Fritzinger D.C., Dean R., Meschter C., Wong K., Halter R., Borlak J., St.John W.D., Vogel C.-W. Complement depletion with humanized cobra venom factor in a mouse model of age-related macular degeneration. Adv. Exp. Med. Biol. 2010, 703:151-162.
32. Fritzinger D.C., Ferreira V.P., Hew B.E., St.John W., Pangburn M.K., Vogel C.-W. A novel concept for the treatment of paroxysmal nocturnal haemoglobinuria (PNH): complement depletion with a human C3 derivative with cobra venom factor-like activity prevents lysis of PNH erythrocytes. Mol. Immunol. 2008, 45:4177.
33. Fritzinger D.C., Hew B.E., Lee J.Q., Newhouse J., Alam M., Ciallella J.R., Bowers M., Gorsuch W.B., Guikema B.J., Stahl G.L., Vogel C.-W. Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents. Adv. Exp. Med. Biol. 2008, 632:293-307.
34. Fritzinger D.C., Hew B.E., Lee J.Q., St.John W., Scaife M., Wilson S., Vogel C.-W. Human C3/cobra venom factor hybrid proteins for therapeutic complement depletion: in vivo activity and lack of toxicity in primates. Mol. Immunol. 2008, 45:4112.
35. Fritzinger D.C., Hew B.E., Pangburn M.K., Janssen B.J.C., Gros P., Vogel C.-W. Human C3/cobra venom factor hybrid proteins with potential therapeutic applications. Mol. Immunol. 2006, 43:141-142.
36. Fritzinger D.C., Hew B.E., Pangburn M.K., Vogel C.-W. Generation of human C3 derivatives with CVF-like function for therapeutic complement depletion. FASEB J. 2005, 19:A324.
37. Fritzinger D.C., Hew B.E., Thorne M., Pangburn M.K., Janssen B.J.C., Gros P., Vogel C.-W. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion. Dev. Comp. Immunol. 2009, 33:105-116.
38. Fritzinger D.C., Hew B.E., Thorne M., Vogel C.-W. Functional characterization of cobra venom factor/cobra C3 hybrid proteins. Mol. Immunol. 2004, 41:230.
39. Fritzinger D.C., Petrella E.C., Connelly M.B., Bredehorst R., Vogel C.-W. Primary structure of cobra complement component C3. J. Immunol. 1992, 149:3554-3562.
40. Gorsuch W.B., Chrysanthou E., Schwaeble W.J., Stahl G.L. The complement system in ischemia-reperfusion injuries. Immunobiology 2012, 217:1026-1033.
41. Gorsuch W.B., Guikema B.J., Fritzinger D.C., Vogel C.-W., Stahl G.L. Humanized cobra venom factor decreases myocardial ischemia-reperfusion injury. Mol. Immunol. 2009, 47:506-510.
42. Götze O., Müller-Eberhard H.J. The C3-activator system: an alternate pathway of complement activation. J. Exp. Med. 1971, 134:90s-108s.
43. x structures. Glycobiology 2001, 11:195-208.
44. Gowda D.C., Petrella E.C., Raj T.T., Bredehorst R., Vogel C.-W. Immunoreactivity and function of oligosaccharides in cobra venom factor. J. Immunol. 1994, 152:2977-2986.
45. Gowda D.C., Schultz M., Bredehorst R., Vogel C.-W. Structure of the major oligosaccharide of cobra venom factor. Mol. Immunol. 1992, 29:335-342.
46. Grier A.H., Schultz M., Vogel C.-W. Cobra venom factor and human C3 share carbohydrate antigenic determinants. J. Immunol. 1987, 139:1245-1252.
47. Grunwald T., Ziegelmüller P., Ollert M.W., Bredehorst R., Vogel C.-W. Cobra venom factor: an intact β-chain is not required for activity. Mol. Immunol. 1993, 30:13.
48. Hageman G.S., Anderson D.H., Johnson L.V., Hancox L.S., Taiber A.J., Hardisty L.I., Hageman J.L., Stockman H.A., Borchardt J.D., Gehrs K.M., Smith R.J., Silvestri G., Russell S.R., Klaver C.C., Barbazetto I., Chang S., Yannuzzi L.A., Barile G.R., Merriam J.C., Smith R.T., Olsh A.K., Bergeron J., Zernant J., Merriam J.E., Gold B., Dean M., Allikmets R. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:7227-7232.
49. Haines J.L., Hauser M.A., Schmidt S., Scott W.K., Olson L.M., Gallins P., Spencer K.L., Kwan S.Y., Noureddine M., Gilbert J.R., Schnetz-Boutaud N., Agarwal A., Postel E.A., Pericak-Vance M.A. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005, 308:419-421.
50. Hart M.L., Ceonzo K.A., Shaffer L.A., Takahashi K., Rother R.P., Reenstra W.R., Buras J.A., Stahl G.L. Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J. Immunol. 2005, 174:6373-6380.
51. Hebell T., Ahearn J.M., Fearon D.T. Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science 1991, 254:102-105.
52. Hensley P., O'Keefe M.C., Spangler C.J., Osborne J.C., Vogel C.-W. The effects of metal ions and temperature on the interaction of cobra venom factor and human complement factor B. J. Biol. Chem. 1986, 261:11038-11044.
53. Hew B.E., Wong K., Lee J.Q., Pangburn M., Vogel C.-W., Fritzinger D.C. Understanding the structural basis of convertase stability: fine mapping of residues required for CVF-like activity in human C3/CVF hybrid proteins. Mol. Immunol. 2010, 47:2257.
54. Hew B.E., Lee J.Q., Awakuni J., Fritzinger D.C., Vogel C.-W. Human C3/cobra venom factor hybrid proteins for therapeutic complement depletion: fine mapping of structure/function relationships. Mol. Immunol. 2008, 45:4120.
55. Hew B.E., Thorne M., Fritzinger D.C., Vogel C.-W. Humanized cobra venom factor (CVF): generation of human C3 derivatives with CVF-like function. Mol. Immunol. 2004, 41:244-245.
56. Hew B.E., Wehrhahn D., Fritzinger D.C., Vogel C.-W. Hybrid proteins of cobra venom factor and cobra C3: tools to identify functionally important regions in cobra venom factor. Toxicon 2012, 60:632-647.
57. Hillmen P., Hall C., Marsh J.C., Elebute M., Bombara M.P., Petro B.E., Cullen M.J., Richards S.J., Rollins S.A., Mojcik C.F., Rother R.P. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 2004, 350:552-559.
58. Holers V.M., Girardi G., Mo L., Guthridge J.M., Molina H., Pierangeli S.S., Espinola R., Xiaowei L.E., Mao D., Vialpando C.G., Salmon J.E. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J. Exp. Med. 2002, 195:211-220.
59. Holers V.M., Thurman J.M. The alternative pathway of complement in disease: opportunities for therapeutic targeting. Mol. Immunol. 2004, 41:147-152.
60. Huda R., Fritzinger D.C., Finnegan P.F., Christadoss P., Vogel C.-W.E. Complement depletion with humanized cobra venom factor (CVF) improves the severity of experimental autoimmune myasthenia gravis (EAMG). Mol. Immunol. 2011, 48:1712.
61. Jacobs T., Andrä J., Gaworski I., Graefe S., Mellenthin K., Krömer M., Halter R., Borlak J., Clos J. Complement C3 is required for the progression of cutaneous lesions and neutrophil attraction in Leishmania major infection. Med. Microbiol. Immunol. 2005, 194:143-149.
62. Jacobson M.P., Pincus D.L., Rapp C.S., Day T.J., Honig B., Shaw D.E., Friesner R.A. A hierarchical approach to all-atom protein loop prediction. Proteins 2004, 55:351-367.
63. Janssen B.J., Christodoulidou A., McCarthy A., Lambris J.D., Gros P. Structure of C3b reveals conformational changes that underlie complement activity. Nature 2006, 444:213-216.
64. Janssen B.J., Gomes L., Koning R.I., Svergun D.I., Koster A.J., Fritzinger D.C., Vogel C.-W., Gros P. Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex. EMBO J. 2009, 28:2469-2478.
65. Janssen B.J., Huizinga E.G., Raaijmakers H.C., Roos A., Daha M.R., Nilsson-Ekdahl K., Nilsson B., Gros P. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 2005, 437:505-511.
66. Jordon R.E., Day N.K., Sams W.M., Good R.A. The complement system in bullous pemphigoid I. Complement and component levels in sera and blister fluids. J. Clin. Invest. 1973, 52:1207-1214.
67. Kaplan H.J., Leibole M.A., Tezel T., Ferguson T.A. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat. Med. 1999, 5:292-297.
68. Kavanagh D., Richards A., Atkinson J. Complement regulatory genes and hemolytic uremic syndromes. Annu. Rev. Med. 2008, 59:293-309.
69. Kerwar S.S., Bauman N., Oronsky A.L., Sloboda A.E. Studies on type II collagen induced polyarthritis in rats. Effect of complement depletion. J. Immunopharmacol. 1981, 3:323-337.
70. Kock M.A., Hew B.E., Bammert H., Fritzinger D.C., Vogel C.-W. Structure and function of recombinant cobra venom factor. J. Biol. Chem. 2004, 279:30836-30843.
71. Köhl J. Drug evaluation: the C5a receptor antagonist PMX-53. Curr. Opin. Mol. Ther. 2006, 8:529-538.
72. Kölln J., Bredehorst R., Spillner E. Engineering of human complement component C3 for catalytic inhibition of complement. Immunol. Lett. 2005, 98:49-56.
73. Kölln J., Spillner E., Andrä J., Klensang K., Bredehorst R. Human C3 derivatives engineered for decomplementation by forming stable C3 convertases. Mol. Immunol. 2004, 41:259.
74. Kölln J., Spillner E., Andrä J., Klensang K., Bredehorst R. Complement inactivation by recombinant human C3 derivatives. J. Immunol. 2004, 173:5540-5545.
75. Krishnan V., Ponnuraj K., Xu Y., Macon K., Volanakis J.E., Narayana S.V. The crystal structure of cobra venom factor, a cofactor for C3- and C5-convertase CVFBb. Structure 2009, 17:611-619.
76. Lachmann P.J., Halbwachs L. The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin. Exp. Immunol. 1975, 21:109-114.
77. Lachmann P.J., Smith R.A. Taking complement to the clinic - has the time finally come?. Scand. J. Immunol. 2009, 69:471-478.
78. Lennon V.A., Seybold M.E., Lindstrom J.M., Cochrane C., Ulevitch R. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J. Exp. Med. 1978, 147:973-983.
79. Lesavre P.H., Hugli T.E., Esser A.F., Müller-Eberhard H.J. The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J. Immunol. 1979, 123:529-534.
80. Leventhal J.R., Dalmasso A.P., Cromwell J.W., Platt J.L., Manivel C.J., Bolman R.M., Matas A.J. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993, 55:857-865.
81. Linton S.M., Morgan B.P. Complement activation and inhibition in experimental models of arthritis. Mol. Immunol. 1999, 36:905-914.
82. Lundwall Å., Hellman U., Eggertsen G., Sjöquist J. Chemical characterization of cyanogen bromide fragments from the β-chain of human complement factor C3. FEBS Lett. 1984, 169:57-62.
83. Maillard J.L., Zarco R.M. Décomplémentation par un facteur extrait du venin de cobra Effect sur plusieurs reactions immunes du cobaye et du rat. Ann. Inst. Pasteur (Paris) 1968, 114:756-774.
84. McCleary R.J., Kini R.M. Non-enzymatic proteins from snake venoms: a gold mine of pharmacological tools and drug leads. Toxicon 2013, 62:56-74.
85. Medicus R.G., Götze O., Müller-Eberhard H.J. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J. Exp. Med. 1976, 144:1076-1093.
86. Miller H., Miller B., Ishibashi T., Ryan S.J. Pathogenesis of laser-induced choroidal subretinal neovascularization. Invest. Ophthalmol. Vis. Sci. 1990, 31:899-908.
87. Misumi Y., Oda K., Fujiwara T., Takami N., Tashiro K., Ikehara Y. Functional expression of furin demonstrating its intracellular localization and endoprotease activity for processing of proalbumin and complement pro-C3. J. Biol. Chem. 1991, 266:16954-16959.
88. Morgan B.P., Harris C.L. Complement therapeutics; history and current progress. Mol. Immunol. 2003, 40:159-170.
89. Müller-Eberhard H.J., Fjellström K.E. Isolation of the anticomplementary protein from cobra venom and its mode of action on C3. J. Immunol. 1971, 107:1666-1672.
90. Mulligan M.S., Schmid E., Beck-Schimmer B., Till G.O., Friedl H.P., Brauer R.B., Hugli T.E., Miyasaka M., Warner R.L., Johnson K.J., Ward P.A. Requirement and role of C5a in acute lung inflammatory injury in rats. J. Clin. Invest. 1996, 98:503-512.
91. Nagaki K., Iida K., Okubo M., Inai S. Reaction mechanisms of beta1H globulin. Int. Arch. Allergy Appl. Immunol. 1978, 57:221-232.
92. Nelson R.A. A new concept of immunosuppression in hypersensitivity reactions and in transplantation immunity. Surv. Ophthalmol. 1966, 11:498-505.
93. Nishimura J., Phillips K.L., Ware R.E., Hall S., Wilson L., Gentry T.L., Howard T.A., Murakami Y., Shibano M., Machii T., Gilboa E., Kanakura Y., Takeda J., Kinoshita T., Rosse W.F., Smith C.A. Efficient retrovirus-mediated PIG-A gene transfer and stable restoration of GPI-anchored protein expression in cells with the PNH phenotype. Blood 2001, 97:3004-3010.
94. Pangburn M.K., Müller-Eberhard H.J. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem. J. 1986, 235:723-730.
95. Pangburn M.K., Schreiber R.D., Müller-Eberhard H.J. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J. Exp. Med. 1977, 146:257-270.
96. Parker C.J., Wiedmer T., Sims P.J., Rosse W.F. Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes. J. Clin. Invest. 1985, 75:2074-2084.
97. Qian J., Borovok M., Bi L., Kazazian H.H., Hoyer L.W. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb. Haemost. 1999, 81:240-244.
98. Rawal N., Pangburn M.K. Functional role of the noncatalytic subunit of complement C5 convertase. J. Immunol. 2000, 164:1379-1385.
99. Rawal N., Pangburn M.K. Structure/function of C5 convertases of complement. Int. Immunopharmacol. 2001, 1:415-422.
100. Rayes J., Ing M., Peyron I., Dimitrov J.D., Delignat S., Fritzinger D.C., Vogel C.-W., Fremeaux-Bacchi V., Kaveri S.V., Roumenina L., Lacroix-Desmazes S. Complement depletion with humanized cobra venom factor reduces the immune response against therapeutic factor VIII in hemophilia A. Mol. Immunol. 2014, (in this issue).
101. Rayes J., Ing M., Peyron I., Fritzinger D.C., Vogel C.-W., Kaveri S., Lacroix-Desmazes S. Humanized cobra venom factor exhibits virtual absence of immunogenicity in mice compared to natural CVF. Mol. Immunol. 2014, 61:191-203.
102. Rehana S., Kini M.R. Molecular isoforms of cobra venom factor-like proteins in the venom of Austrelaps superbus. Toxicon 2007, 50:32-52.
103. Repesse Y., Peyron I., Dimitrov J.D., Dasgupta S., Moshai E.F., Costa C., Borel-Derlon A., Guillet B., D'Oiron R., Aouba A., Rothschild C., Oldenburg J., Pavlova A., Kaveri S.V., Lacroix-Desmazes S. Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter. Haematologica 2013, 98:1650-1655.
104. Ricklin D., Lambris J.D. Compstat a complement inhibitor on its way to clinical application. Adv. Exp. Biol. Med. 2008, 632:273-292.
105. Ricklin D., Lambris J.D. Progress and trends in complement therapeutics. Adv. Exp. Med. Biol. 2013, 735:1-22.
106. Riedemann N.C., Ward P.A. Complement in ischemia reperfusion injury. Am. J. Pathol. 2003, 162:363-367.
107. Rooijakkers S.H., Wu J., Ruyken M., van Domselaar R., Planken K.L., Tzekou A., Ricklin D., Lambris J.D., Janssen B.J., van Strijp J.A., Gros P. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat. Immunol. 2009, 10:721-727.
108. Roth A., Hock C., Konik A., Christoph S., Duhrsen U. Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena. Int. J. Hematol. 2011, 93:704-714.
109. Sjöholm A.G., Jönsson G., Braconier J.H., Sturfelt G., Truedsson L. Complement deficiency and disease: an update. Mol. Immunol. 2006, 43:78-85.
110. Smith C.A., Vogel C.-W., Müller-Eberhard H.J. Ultrastructure of cobra venom factor-dependent C3/C5 convertase and its zymogen, factor B of human complement. J. Biol. Chem. 1982, 257:9879-9882.
111. Smith C.A., Vogel C.-W., Müller-Eberhard H.J. MHC class III products: an electron microscopic study of the C3 convertases of human complement. J. Exp. Med. 1984, 159:324-329.
112. Stahl G.L., Xu Y., Hao L., Miller M., Buras J.A., Fung M., Zhao H. Role for the alternative complement pathway in ischemia/reperfusion injury. Am. J. Pathol. 2003, 162:449-455.
113. Sylvestre D., Clynes R., Ma M., Warren H., Carroll M.C., Ravetch J.V. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J. Exp. Med. 1996, 184:2385-2392.
114. Takahashi K., Saha D., Shattino I., Pavlov V.I., Stahl G.L., Finnegan P., Melo M.F. Complement 3 is involved with ventilator-induced lung injury. Int. Immunopharmacol. 2011, 11:2138-2143.
115. Till G.O., Johnson K.J., Kunkel R., Ward P.A. Intravascular activation of complement and acute lung injury. Dependency on neutrophils and toxic oxygen metabolites. J. Clin. Invest. 1982, 69:1126-1135.
116. Till G.O., Morganroth M.L., Kunkel R., Ward P.A. Activation of C5 by cobra venom factor is required in neutrophil-mediated lung injury in the rat. Am. J. Pathol. 1987, 129:44-53.
117. Tomana M., Niemann M., Garner C., Volanakis J.E. Carbohydrate composition of the second, third and fifth components and factors B and D of human complement. Mol. Immunol. 1985, 22:107-111.
118. Van den Berg C.W., Aerts P.C., Van Dijk H. In vivo anti-complementary activities of the cobra venom factors from Naja naja and Naja haje. J. Immunol. Methods 1991, 136:287-294.
119. Vik D.P., Amiguet P., Moffat G.J., Fey M., Amiguet-Barras F., Wetsel R.A., Tack B.F. Structural features of the human C3 gene: intron/exon organization, transcriptional start site, and promoter region sequence. Biochemistry 1991, 30:1080-1085.
120. Vogel C.-W. Cobra venom factor, the complement-activating protein of cobra venom. Handbook of Natural Toxins: Reptile and Amphibian Venoms 1991, 147-188. Marcel Dekker, New York. A.T. Tu (Ed.).
121. Vogel C.-W. From medicine to toxinology and back to medicine, and the eternal role of snakes in therapy. Toxicon 2012, 60:139.
122. Vogel C.-W., Bredehorst R., Fritzinger D.C., Grunwald T., Ziegelmüller P., Kock M.A. Structure and function of cobra venom factor, the complement-activating protein in cobra venom. Adv. Exp. Med. Biol. 1996, 391:97-114.
123. Vogel C.-W., Fritzinger D.C., Gorsuch W.B., Stahl G.L. Complement depletion with humanized cobra venom factor: efficacy in preclinical models of vascular diseases. Thromb. Haemost. 2014, (in press).
124. Vogel C.-W., Fritzinger D.C. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion. Curr. Pharm. Des. 2007, 13:2916-2926.
125. Vogel C.-W., Fritzinger D.C. Cobra venom factor: structure, function, and humanization for therapeutic complement depletion. Toxicon 2010, 56:1198-1222.
126. Vogel C.-W., Fritzinger D.C., Hew B.E., Thorne M., Bammert H. Recombinant cobra venom factor. Mol. Immunol. 2004, 41:191-1999.
127. Vogel C.-W., Müller-Eberhard H.J. The cobra venom factor-dependent C3 convertase of human complement. A kinetic and thermodynamic analysis of a protease acting on its natural high molecular weight substrate. J. Biol. Chem. 1982, 257:8292-8299.
128. Vogel C.-W., Müller-Eberhard H.J. Cobra venom factor: improved method for purification and biochemical characterization. J. Immunol. Methods 1984, 73:203-220.
129. Vogel C.-W., Smith C.A., Müller-Eberhard H.J. Cobra venom factor: structural homology with the third component of human complement. J. Immunol. 1984, 133:3235-3241.
130. Vogt W., Dieminger L., Lynen R., Schmidt G. Alternative pathway for the activation of complement in human serum. Formation and composition of the complex with cobra venom factor that cleaves the third component of complement. Hoppe Seyler's Z. Physiol. Chem. 1974, 355:171-183.
131. Vogt W., Schmidt G., Von Buttlar B., Dieminger L. A new function of the activated third component of complement: binding to C5, an essential step for C5 activation. Immunology 1978, 34:29-40.
132. von Zabern I., Hinsch B., Przyklenk H., Schmidt G., Vogt W. Comparison of Naja n. naja and Naja h. haje cobra-venom factors: correlation between binding affinity for the fifth component of complement and mediation of its cleavage. Immunobiology 1980, 157:499-514.
133. Walsh M.C., Bourcier T., Takahashi K., Shi L., Busche M.N., Rother R.P., Solomon S.D., Ezekowitz R.A., Stahl G.L. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J. Immunol. 2005, 175:541-546.
134. Wang S.Y., Racila E., Taylor R.P., Weiner G.J. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 2008, 111:1456-1463.
135. Wang S.Y., Veeramani S., Racila E., Cagley J., Fritzinger D.C., Vogel C.-W., St John W., Weiner G.J. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 2009, 114:5322-5330.
136. Wang Y., Rollins S.A., Madri J.A., Matis L.A. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:8955-8959.
137. Wehrhahn D., Meiling K., Fritzinger D.C., Bredehorst R., Andrä J., Vogel C.-W. Analysis of the structure/function relationship of cobra venom factor (CVF) and C3: generation of CVF/cobraC3 hybrid proteins. Immunopharmacology 2000, 49:94.
138. Whaley K., Ruddy S. Modulation of the alternative complement pathways by beta1H globulin. J. Exp. Med. 1976, 144:1147-1163.
139. Wiesmann C., Katschke K.J., Yin J., Helmy K.Y., Steffek M., Fairbrother W.J., McCallum S.A., Embuscado L., DeForge L., Hass P.E., van Lookeren Campagne M. Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 2006, 444:217-220.
140. Zeng L., Sun Q.-Y., Jin Y., Zhang Y., Lee W.-H., Zhang Y. Molecular cloning and characterization of a complement-depleting factor from king cobra, Ophiophagus hannah. Toxicon 2012, 60:290-301.
141. Zhao H., Montalto M.C., Pfeiffer K.J., Hao L., Stahl G.L. Murine model of gastrointestinal ischemia associated with complement-dependent injury. J. Appl. Physiol. 2002, 93:338-345.